0001104659-19-059509.txt : 20191104 0001104659-19-059509.hdr.sgml : 20191104 20191104161635 ACCESSION NUMBER: 0001104659-19-059509 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191031 FILED AS OF DATE: 20191104 DATE AS OF CHANGE: 20191104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Astley-Sparke Philip CENTRAL INDEX KEY: 0001376491 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38596 FILM NUMBER: 191190000 MAIL ADDRESS: STREET 1: C/O BIOVEX GROUP, INC. STREET 2: 34 COMMERCE WAY CITY: WOBURN STATE: MA ZIP: 10801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Replimune Group, Inc. CENTRAL INDEX KEY: 0001737953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822082553 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: DE ZIP: 01801 BUSINESS PHONE: (781) 222-9600 MAIL ADDRESS: STREET 1: 500 UNICORN PARK CITY: WOBURN STATE: DE ZIP: 01801 4 1 a4.xml 4 X0306 4 2019-10-31 0 0001737953 Replimune Group, Inc. REPL 0001376491 Astley-Sparke Philip C/O REPLIMUNE GROUP, INC. 18 COMMERCE WAY WOBURN MA 01801 1 1 0 0 Executive Chairman Common Stock 2019-10-31 4 S 0 14500 17.00 D 1413297 D The sale reported on this Form 4 was made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Following the sale reported on this Form 4, the reporting person continues to beneficially own 1,413,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 382,571 shares of the Issuer's common stock, 94,103 of which are exercisable as of the date hereof. /s/ Robert Coffin, attorney-in-fact 2019-11-04